Advertisement
Canada markets close in 4 hours 35 minutes
  • S&P/TSX

    22,320.08
    +60.61 (+0.27%)
     
  • S&P 500

    5,194.49
    +13.75 (+0.27%)
     
  • DOW

    38,936.02
    +83.75 (+0.22%)
     
  • CAD/USD

    0.7304
    -0.0017 (-0.24%)
     
  • CRUDE OIL

    78.16
    -0.32 (-0.41%)
     
  • Bitcoin CAD

    87,427.02
    +808.06 (+0.93%)
     
  • CMC Crypto 200

    1,327.81
    -37.32 (-2.73%)
     
  • GOLD FUTURES

    2,324.60
    -6.60 (-0.28%)
     
  • RUSSELL 2000

    2,075.57
    +14.90 (+0.72%)
     
  • 10-Yr Bond

    4.4350
    -0.0540 (-1.20%)
     
  • NASDAQ

    16,377.74
    +28.49 (+0.17%)
     
  • VOLATILITY

    13.51
    +0.02 (+0.15%)
     
  • FTSE

    8,318.20
    +104.71 (+1.27%)
     
  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     
  • CAD/EUR

    0.6774
    -0.0018 (-0.26%)
     

Could This Drug News Lift AbbVie's Stock?

Could This Drug News Lift AbbVie's Stock?

Consider AbbVie's (NYSE: ABBV) crown jewel drug, Humira, which hauled in $21.2 billion in revenue in 2022. The good news is that AbbVie knew this day would come and has been preparing. SLE is an autoimmune disease that affects multiple organs of the body.